* This is the Professional Version. *
Uterine sarcomas are a group of disparate, highly malignant cancers developing from the uterine corpus.
Sarcomas account for < 5% of uterine cancers. Risk factors are similar to those for endometrial carcinoma (see Etiology). The most common types are mixed mesodermal tumors (carcinosarcoma, in which the sarcoma is mixed with adenocarcinoma; formerly called malignant mixed müllerian tumor), leiomyosarcomas, and endometrial stromal tumors.
Symptoms usually prompt transvaginal ultrasonography and endometrial biopsy or fractional D & C. If cancer is identified, CT or MRI is typically done preoperatively.
Staging is done surgically as follows:
Prognosis is generally poorer than that with endometrial cancer of similar stage; survival is generally poor when the cancer has spread beyond the uterus. Histology is not an independent prognostic factor. In one study, 5-yr survival rates were 51% for stage I, 13% for stage II, 10% for stage III, and 3% for stage IV. Most commonly, the cancer recurs locally, in the abdomen, and the lungs.
Treatment is total abdominal hysterectomy and bilateral salpingo-oophorectomy with complete exploration of the abdomen. Pelvic and para-aortic nodes are dissected in patients with carcinosarcoma. The usefulness of lymphadenectomy in patients with leiomyosarcoma or endometrial stromal sarcoma is controversial; no therapeutic value has been shown.
Adjuvant radiation therapy is typically used and appears to delay local recurrence but does not improve overall survival rate. Chemotherapy drugs are typically used when tumors are advanced or recur; drugs vary by tumor type. Most patients with carcinosarcoma are treated with carboplatin plus paclitaxel. Routine treatment for leiomyosarcoma is gemcitabine plus docetaxel. Overall, response to chemotherapy is poor, although progestins are frequently effective for endometrial stromal tumors.
Drug NameSelect Brand Names
carboplatinNo US brand name
* This is a professional Version *